Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome
A legfontosabb adatok
- Ki végzi
- Children's Hospital of Fudan University
- Hol
- Kína9 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 120 fő, tervezett
- Kezdés
- 2026. aug. 20.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Zuberitamab
- standard corticosteroid treatment
- A regiszteradat frissítve
- 2026. augusztus 14.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for children and teenagers with a first episode of steroid-sensitive nephrotic syndrome, a kidney condition. They must already be in full remission after steroid treatment.
- Életkor
- 1 Year to 18 Years
- Nem
- All sexes can join.
- A betegség stádiuma
- Newly diagnosed steroid-sensitive nephrotic syndrome by the 2023 IPNA criteria. Complete remission after steroid treatment before entry: UPCR <= 20 mg/mmol (0.2 mg/mg), or negative or trace urine dipstick on three or more days in a row. Kidney filtration rate (eGFR) >= 90 mL/min/ 1.73 m2.
- Korábbi kezelés
- Must have had steroid treatment that brought remission. No other immune-suppressing drugs within 3 months before entry, other than steroids. No earlier use of biological agents. No live vaccine within one month before entry.
- Biomarker vagy leletérték
- Blood CD20+ (measured as CD19+) cells >= 1% of total lymphocytes.
A részvétel fő kizáró okai
- Nephrotic syndrome with a known cause, such as congenital, IgA nephropathy, lupus nephritis or other secondary forms.
- Low blood counts, raised liver tests, positive autoimmune markers or low complement C3.
- Serious or chronic infections, including tuberculosis, hepatitis B or C, EBV, CMV or HIV.
- Heart failure, severe heart rhythm problems, uncontrolled blood pressure, or severe brain, liver, blood or hormone disorders.
- Autoimmune disease, immune deficiency, cancer, organ transplant, or allergy to the study drugs or sulfamethoxazole.
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Newly diagnosed steroid-sensitive nephrotic syndrome (SSNS) according to the 2023 IPNA criteria, who achieved complete remission after steroid induction therapy prior to study entry, defined as UPCR (based on first morning void or 24 h urine sample) <= 20 mg/mmol (0.2 mg/mg), or negative or trace dipstick on three or more consecutive days
- An estimated glomerular filtration rate >= 90 mL/min/ 1.73 m2 at study entry
- Peripheral blood CD20+ (detected as CD19+) cells >= 1% of total lymphocytes
- No use of other immunosuppressants within 3 months prior to study entry, other than steroids for nephrotic syndrome
Ki nem vehet részt
- Evidence of the following infections: severe or opportunistic infection within the previous 6 months (active tuberculosis or history of tuberculosis or suspected tuberculosis; chronic active infections such as EBV, CMV; active hepatitis B presentation or history, or hepatitis C or hepatitis B virus carrier; HIV infection; or other active viral infections)
- Receipt of live vaccine within one month prior to study entry
- History of previous use of biological agents
- Known etiology including congenital nephrotic syndrome, IgA nephropathy, Henoch-Schönlein purpura nephritis, lupus nephritis, or other secondary nephrotic syndromes
- Current examination suggestive of heart failure, severe arrhythmia, angina pectoris (CTCAE Grade 4), or uncontrolled blood pressure
- Severe diseases of vital organs such as the brain or liver, or suffering from hematological or endocrine system disorders
- Diagnosis of co-existing autoimmune diseases, primary immunodeficiency, or malignancy
- History of organ transplantation (excluding cornea and hair transplants)
- Known allergy to methylprednisolone, Zuberitamab injection active ingredients or any excipients, sulfamethoxazole (or a contraindication to this drug due to G6PD deficiency)
- Investigator's judgment that the patient is unsuitable for participation in this study (e.g., patient is highly likely to be lost to follow-up or provide false results, such as alcohol dependence or psychiatric illness)
- Patients exhibiting any of the following abnormal clinical laboratory values: leukopenia (white blood cells <= 3.0 × 10\^9/L), absolute neutrophil count < 1.5 × 10\^9/L; moderate to severe anemia (hemoglobin < 9.0 g/dL); thrombocytopenia (platelet count < 100 × 10\^12/L); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal; positive for any autoimmune markers (ANA, ENA, ANCA, etc.) or decreased complement C3 levels
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 1 és 18 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn whether adding Zuberitamab to standard corticosteroid therapy can help prevent relapse in children and adolescents aged 1 to 18 years with newly diagnosed steroid-sensitive nephrotic syndrome (SSNS). It will also learn about the safety of Zuberitamab.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* Does Zuberitamab plus standard corticosteroid therapy prolong the time to first relapse compared with standard corticosteroid therapy alone? * What medical problems do participants experience during treatment?
Researchers will compare Zuberitamab plus standard corticosteroid therapy to standard corticosteroid therapy alone to see whether adding Zuberitamab improves disease control.
Participants will:
* Receive standard corticosteroid treatment for approximately 12 weeks, with or without a single intravenous infusion of Zuberitamab after achieving remission * Take preventive antibiotics if they are in the Zuberitamab group * Test their urine daily at home using dipsticks and record results in a diary * Visit the clinic for regular checkups and blood and urine tests during follow-up for up to 12 months
A vizsgálat 2 csoportja
- Zuberitamab + Standard corticosteroid treatmentA vizsgált kezelés
Zuberitamab plus standard corticosteroid treatment: Zuberitamab 375 mg/m2 (max 500 mg) as a single IV dose after remission. Premedication 30 min prior includes oral antipyretic and antihistamine and IV methylprednisolone 1.6 mg/kg (max 48 mg); oral steroid withheld on infusion day. Standard corticosteroid treatment consists of oral prednisone/prednisolone per protocol taper. TMP-SMZ prophylaxis (TMP 3 mg/kg on alternate days, max SMZ 960 mg) is administered until CD19 recovery. Relapse is managed per protocol with corticosteroid re-induction and possible repeat zuberitamab after remission. Permitted and prohibited concomitant medications are the same as in the comparator arm.
Kezelés: Zuberitamab és standard corticosteroid treatment
- Standard corticosteroid treatment OnlyMár használt kezelés, összehasonlításként
Standard corticosteroid treatment: oral prednisone/prednisolone 2 mg/kg/day (max 60 mg) for 6 weeks, followed by 1.5 mg/kg (max 40 mg) on alternate days for 6 weeks, then discontinue. No zuberitamab, TMP-SMZ prophylaxis, or infusion premedication is given during initial treatment. Relapse is managed per protocol with corticosteroid re-induction; participants may receive zuberitamab after remission is re-achieved according to predefined criteria. Permitted concomitant medications include antihypertensives, calcium supplementation, anti-infective agents, antihistamines, anticoagulants, IVIG, hepatoprotective agents, glucose-lowering medications, and ophthalmic treatments. Prohibited therapies include other immunosuppressants (rituximab, CNIs, MMF, cyclophosphamide, plasma exchange) and Chinese herbal medicines for nephrotic syndrome (e.g., Huangkui, Huaiqihuang, Tripterygium). Live vaccines are prohibited during B-cell depletion.
Kezelés: standard corticosteroid treatment
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy and Safety of Single-dose Zuberitamab in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter Randomized Controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Illeszkedési kérdések
- Forrás: NCT07765914: ki vehet részt
- A regiszteradat frissítve
- 2026. augusztus 14.